Navigation Links
VisEn Medical Raises $5.0 Million in Expanded Series B Financing
Date:4/18/2008

WOBURN, Mass., April 18 /PRNewswire/ -- VisEn Medical, Inc., a leader in fluorescence in vivo imaging, today announced the expansion of its Series B financing. Merck Capital Ventures and Flagship Ventures co-led this $5.0 million expansion of the Series B round, which initially raised $7 million in November 2007, bringing the total Series B financing amount to $12.0 million. VisEn will use the additional financing to further advance its proprietary fluorescence in vivo imaging product pipelines, and to expand its commercial applications and customer support of its marketed products worldwide.

"We are pleased to have Merck Capital and Flagship Ventures deepen and extend their support of our company and our programs," said Kirtland Poss, President and Chief Executive Officer of VisEn Medical. "Based on our progress since the first Series B closing, the results that customers are achieving with our systems and agents, some key new product launches, and the strong commercial traction we are already seeing in 2008, our Board and our investors have decided to increase their support to accelerate our growth."

"We invest in emerging companies with proven technologies that support the pharmaceutical industry," said Per Lofberg, President and Chief Executive Officer of Merck Capital Ventures and a member of the Board of VisEn. "VisEn is a market leader in fluorescence in vivo imaging pre-clinically, and well positioned to advance into human clinical trials with its technology platforms. These translational linkages are of growing importance in the pharmaceutical and healthcare industries, and we are pleased to participate in this opportunity."

Ed Kania, Chairman of VisEn Medical and Managing Partner of Flagship Ventures noted, "We see tremendous value and promise in VisEn's technologies and products, its deep customer relationships with a growing number of leading pharmaceutical companies, and its early progress driving the translation of its preclinical technologies into eventual clinical use. We are pleased to continue our strong support and participation with VisEn in these areas."

About VisEn Medical, Inc.

VisEn Medical, Inc. was founded in 2000 based on fluorescence in vivo imaging technologies initially developed by industry-leading researchers and clinicians at the Massachusetts General Hospital and Harvard Medical School. VisEn develops and commercializes the industry's highest performing fluorescence in vivo imaging technology platforms, from research through medicine. The Company also works directly with large pharmaceutical partners to design ranges of tailored molecular imaging probes and applications that are targeted to their specific research areas. Privately-held VisEn is headquartered in Woburn, Massachusetts and has been financed by leading venture firms including Flagship Ventures, Merck Capital Ventures and The Bollard Group. For further information please visit http://www.visenmedical.com.

About Merck Capital Ventures, LLC

Merck Capital Ventures is a subsidiary of Merck & Co., Inc. founded in November 2000. Merck Capital Ventures (MCV) actively invests in emerging businesses with interesting technology in areas related to the commercialization, distribution and delivery of pharmaceuticals and related healthcare services. The focus of MCV is to invest in technologies that accelerate innovation related to the pharmaceutical business and other sectors of health care delivery. For further information, see http://www.merckcapitalventures.com.

About Flagship Ventures

Flagship Ventures is a leading venture capital firm focused on creating, financing, and building innovative companies. Founded in 2000, Flagship operates from its offices at Kendall Square in Cambridge, MA. With an active portfolio of over 40 companies, the firm's strategy is to balance its investments across three principal business sectors: Life Science / Diagnostics Tools, Energy & Technology Platforms, and Therapeutics. Through its unique venture creation and seed investing programs, Flagship actively participates in developing new ventures that are commercializing many of the leading breakthroughs of our times. For more information, visit http://www.flagshipventures.com.


'/>"/>
SOURCE VisEn Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. VisEn Medical Launches FMT(TM) 2500 - Next-Generation Fluorescence Imaging System
2. Aurora St. Lukes Medical Center Installs the Countrys Second-Largest Hyperbaric Chamber
3. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET April 24, 2008 to Discuss First Quarter 2008 Results
4. Correction: Law Offices of Howard G. Smith Announces Investigation on Behalf of Shareholders of Inverness Medical Innovations, Inc.
5. IC Sciences Investigates Application of Narrative Sciences for Medical Informatics Instruments
6. Heritage Victor Valley Medical Group Celebrates Earth Day
7. Medical Tourism Association Announces Worlds Largest Medical Tourism Convention in San Francisco, CA USA - September 9-12, 2008
8. Cedars-Sinai Medical Center opens patient trial of virus that attacks brain cancer cells
9. China Sky One Medical, Inc. Announces Its Successful Participation in the 20th International Medical Instruments and Equipment Exhibition
10. Law Offices of Howard G. Smith Announces Investigation on Behalf of Current and Former Employees of Inverness Medical Innovations, Inc. Who Invested in the Inverness Medical Innovations, Inc. Employee Savings Plan
11. Roseland Medical Center Hosts Recognition Ceremony and Open House
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and Mental ... exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took place ... BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive an ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm ... sciences executive with extensive sequencing and genomics experience, as Vice President of North American ... Hill will be responsible for leading the sales team in the commercialization of the ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Collagen Matrix, Inc., ("Collagen Matrix") the driving ... collagen and mineral based medical devices for tissue ... Messer has joined the company as Vice ... growing portfolio of oral surgery, neurosurgery, orthopaedic and ... the Collagen Matrix executive team as an accomplished ...
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
Breaking Medicine Technology: